Five-year survivors from brain metastases treated with stereotactic radiosurgery: Biology, improving treatments, or just plain luck?
brain metastasis
neurologic death
prolonged survival
Journal
Neuro-oncology practice
ISSN: 2054-2577
Titre abrégé: Neurooncol Pract
Pays: England
ID NLM: 101640528
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
entrez:
27
3
2023
pubmed:
28
3
2023
medline:
28
3
2023
Statut:
epublish
Résumé
Improvements in therapies have led to an increasing number of long-term survivors of brain metastases. The present series compares a population of 5-year survivors of brain metastases to a generalized brain metastases population to assess for factors attributable to long-term survival. A single institution retrospective review was performed to identify 5-year survivors of brain metastases who received stereotactic radiosurgery (SRS). A historical control population of 737 patients with brain metastases was used to assess similarities and differences between the long-term survivor population and the general population treated with SRS. A total of 98 patients with brain metastases were found to have survived over 60 months. No differences between long-term survivors and controls were identified with regards to the age at first SRS ( Five-year survivors of brain metastases represent a diverse histologic population, suggesting a small population of oligometastatic and indolent cancers exist for each cancer type.
Sections du résumé
Background
UNASSIGNED
Improvements in therapies have led to an increasing number of long-term survivors of brain metastases. The present series compares a population of 5-year survivors of brain metastases to a generalized brain metastases population to assess for factors attributable to long-term survival.
Methods
UNASSIGNED
A single institution retrospective review was performed to identify 5-year survivors of brain metastases who received stereotactic radiosurgery (SRS). A historical control population of 737 patients with brain metastases was used to assess similarities and differences between the long-term survivor population and the general population treated with SRS.
Results
UNASSIGNED
A total of 98 patients with brain metastases were found to have survived over 60 months. No differences between long-term survivors and controls were identified with regards to the age at first SRS (
Conclusion
UNASSIGNED
Five-year survivors of brain metastases represent a diverse histologic population, suggesting a small population of oligometastatic and indolent cancers exist for each cancer type.
Identifiants
pubmed: 36970170
doi: 10.1093/nop/npac095
pii: npac095
pmc: PMC10037943
doi:
Types de publication
Journal Article
Langues
eng
Pagination
195-202Subventions
Organisme : NCI NIH HHS
ID : P30 CA012197
Pays : United States
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Déclaration de conflit d'intérêts
Dr Stephen Tatter: Arbor Pharmaceuticals, research support, Monteris Medical Inc., research support. Dr Michael Chan: Monteris Medical Inc., speaker. The remainder of the authors declares no conflicts of interest.
Références
Cancer. 2014 Feb 1;120(3):433-41
pubmed: 24452675
N Engl J Med. 1990 Feb 22;322(8):494-500
pubmed: 2405271
Cancer Discov. 2015 Nov;5(11):1164-1177
pubmed: 26410082
Neuro Oncol. 2014 Sep;16(9):1283-8
pubmed: 24558022
Neurooncol Pract. 2019 Sep;6(5):402-409
pubmed: 31555455
Cureus. 2021 Nov 28;13(11):e19967
pubmed: 34984127
J Clin Neurosci. 2015 Mar;22(3):561-5
pubmed: 25560387
Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):801-9
pubmed: 16904847
JAMA Oncol. 2018 Mar 01;4(3):317-323
pubmed: 29192307
J Neurosurg. 2011 Jun;114(6):1585-91
pubmed: 21166567
Adv Radiat Oncol. 2019 Nov 26;5(3):350-357
pubmed: 32529128
Oncotarget. 2017 Nov 07;8(60):101005-101011
pubmed: 29254141
J Neurooncol. 2016 Sep;129(3):545-555
pubmed: 27456950
Cancer. 2019 Nov 1;125(21):3776-3789
pubmed: 31287564
Neuro Oncol. 2017 Apr 1;19(4):558-566
pubmed: 27571883
Cancer Med. 2013 Jun;2(3):403-11
pubmed: 23930216
Cancer. 1996 Oct 15;78(8):1781-8
pubmed: 8859192
Front Biosci (Schol Ed). 2016 Jan 01;8(1):203-14
pubmed: 26709908
Oncotarget. 2015 Aug 7;6(22):18945-55
pubmed: 26087184
Cancer. 2005 Dec 15;104(12):2784-91
pubmed: 16288488
Neurosurgery. 2019 Mar 1;84(3):558-566
pubmed: 29860451
World Neurosurg. 2022 Jun;162:e401-e415
pubmed: 35283357